Reducing Systemic Inflammation in People on Antiretroviral Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

January 31, 2029

Conditions
Human Immunodeficiency Virus (HIV)Cardiovascular Risk Factor
Interventions
DRUG

Fostemsavir

Addition of fostemsavir to the patient's current antiretroviral regimen: once daily oral administration (Rukobia 600 mg extended-release tablets) for 24 months

Trial Locations (1)

H2X 0A9

CR CHUM, Montreal

All Listed Sponsors
collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

collaborator

Clinique du Quartier Latin

NETWORK

collaborator

BC Women's Hospital & Health Centre

OTHER

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER